MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Ovid therapeutics Inc

Fechado

SetorSaúde

0.43 2.38

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.4

Máximo

0.45

Indicadores-chave

By Trading Economics

Rendimento

-982K

-10M

Vendas

54K

130K

Margem de lucro

-7,873.077

Funcionários

23

EBITDA

-1.8M

-12M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+558.14% upside

Dividendos

By Dow Jones

Próximos Ganhos

12 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.7M

27M

Abertura anterior

-1.95

Fecho anterior

0.43

Sentimento de Notícias

By Acuity

50%

50%

162 / 376 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Ovid therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

9 de jul. de 2025, 15:46 UTC

Grandes Movimentos do Mercado

BitMine Shares Fall After Closing of $250 Million Private Placement

9 de jul. de 2025, 23:44 UTC

Conversa de Mercado

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 de jul. de 2025, 23:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

9 de jul. de 2025, 23:42 UTC

Conversa de Mercado

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 de jul. de 2025, 22:59 UTC

Conversa de Mercado

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 de jul. de 2025, 22:59 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

9 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

9 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de jul. de 2025, 20:26 UTC

Ganhos

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 de jul. de 2025, 19:18 UTC

Conversa de Mercado

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 de jul. de 2025, 19:03 UTC

Conversa de Mercado

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 de jul. de 2025, 18:31 UTC

Conversa de Mercado

Some Fed Officials Supported Considering July Cut -- Market Talk

9 de jul. de 2025, 17:07 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk -2-

9 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

9 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

9 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

9 de jul. de 2025, 16:14 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

9 de jul. de 2025, 16:14 UTC

Conversa de Mercado

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 de jul. de 2025, 16:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 de jul. de 2025, 16:12 UTC

Conversa de Mercado

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 de jul. de 2025, 16:08 UTC

Conversa de Mercado

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 de jul. de 2025, 15:31 UTC

Grandes Movimentos do Mercado

BitMine Shares Fall After Closing of $250M Private Placement

9 de jul. de 2025, 15:31 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 de jul. de 2025, 15:27 UTC

Conversa de Mercado

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 de jul. de 2025, 14:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 de jul. de 2025, 14:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 de jul. de 2025, 14:26 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

9 de jul. de 2025, 14:26 UTC

Conversa de Mercado

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Comparação entre Pares

Variação de preço

Ovid therapeutics Inc Previsão

Preço-alvo

By TipRanks

558.14% parte superior

Previsão para 12 meses

Média 2.83 USD  558.14%

Máximo 4 USD

Mínimo 1.5 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.275 / 0.33Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

162 / 376 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.